EN
NL
FR
CORPORATE
ABOUT DAFRA
VISION/MISSION
HISTORY
PEOPLE
BOARD OF DIRECTORS
PRODUCTS
ANALGESICS
ANTIBIOTICS
ANTIFUNGAL
ANTIHISTAMINICS
ANTI INFECTIVES
CARDIOVASCULAR
GASTRO INTESTINAL
HORMONAL
OTHERS
R&D
ONCOLOGY
GLOBAL HEALTH
MALARIA
WHAT IS MALARIA
CHICORY PROJECT
SCHISTOSOMIASIS
WHAT IS SCHISTOSOMIASIS
NEW HOPE
LEISHMANIASIS
WHAT IS LEISHMANIASIS
TUBERCULOSIS
WHAT IS TUBERCULOSIS
NEW MOLECULE TO TREAT TUBERCULOSIS
LOCAL NETWORK
MALI
LOCAL MARKETS
CONTACT DETAILS
KENYA
LOCAL MARKETS
CONTACT DETAILS
NIGERIA
LOCAL MARKETS
CONTACT DETAILS
PARTNERS
CSRP
PROJECTS
EMPLOYMENT
EDUCATION
HEALTH CARE
CAREERS
HR POLICY
VACANCIES
NEWS
PRESS RELEASE
ARTICLES
CORPORATE
PRODUCTS
R&D
LOCAL NETWORK
PARTNERS
CSRP
CAREERS
NEWS
Home
Press release
Preview
Attachment
Size
Dafra receives exclusive licence from Max Planck Society.pdf
37.76 KB
Nederlands
Français
Português
Secondary links
NEWS
LINKS
CONTACT
Local network
Find out more: Malaria
PRODUCTS
ANALGESICS
ANTIBIOTICS
ANTIFUNGAL
ANTIHISTAMINICS
ANTI INFECTIVES
CARDIOVASCULAR
GASTRO INTESTINAL
HORMONAL
OTHERS
R&D
ONCOLOGY
GLOBAL HEALTH
LOCAL NETWORK
MALI
KENYA
NIGERIA
NEWS
PRESS RELEASE
ARTICLES
Dafra Pharma International
Slachthuisstraat 30/7
B-2300
Turnhout
Belgium
Tel. +32 (0) 14 61 78 20
Fax. +32 (0) 14 61 78 59
